Drug Trial Radar · NCT05115110
A Study to Investigate the Safety and Efficacy of RO7204239 in Combination With Risdiplam (RO7034067) in Participants With Spinal Muscular Atrophy
Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
97
Actual
Start
Jun 2, 2022
Primary completion
Nov 2, 2026
Study completion Nov 2, 2026
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Nov 10, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 2 years, up to 25 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Risdiplam works by helping the body produce more survival motor neuron (SMN) protein throughout the body. This means fewer motor neurons - nerve cells that pass impulses from nerves to muscles to cause movement - are lost, which may improve how well muscles work in people with SMA. RO7204239 is an investigational anti-myostatin antibody that is designed to target myostatin. Myostatin plays an important role in the regulation of skeletal muscle size by controlling growth. Inhibiting myostatin may help muscles grow in size and strength. RO7204239 in combination with risdiplam, which is designed to increase the amount of SMN protein throughout the body, has the potential to further improve motor function and clinical outcomes for people living with SMA. This trial will study the safety and efficacy of RO7204239 in combination with risdiplam in patients with spinal muscular atrophy (SMA). The trial has two parts; Part 1 is the dose-finding part in SMA patients that are either ambulant (aged 2-10 years) or non-ambulant (aged 5-10 years) within separate cohorts, and Part 2 is the pivotal part in SMA patients aged 2-25 years that are ambulant.
Conditions
- Spinal Muscular Atrophy (SMA)
Interventions
RO7204239Drug
RO7204239 will administered every 4 weeks (Q4W) by subcutaneous (SC) injection into the abdomen. RO7204239 will be investigated at low- and high-dose in Part 1.
PlaceboDrug
Placebo will be administered Q4W by SC injection into the abdomen.
RisdiplamDrug
Risdiplam will be administered orally once daily (QD) for the duration of the study.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1 - Percentage of participants with adverse events (AEs)Time frame: Up to 4.5 years
- Part 1 - Incidence of relevant echocardiographic parameter z scores > 2Time frame: Up to 4.5 years
- Part 1 - Serum concentration of RO7204239Time frame: Through Week 96
- Part 1 - Time to maximum serum concentration (Cmax) of RO7204239Time frame: Through Week 96
- Part 1 - Area under the curve (AUC) of RO7204239Time frame: Through Week 96
- Part 1 - Trough concentration (Ctrough) of RO7204239Time frame: Through Week 96
- Part 1 - Plasma concentration of risdiplamTime frame: Week 21
- Part 1 - Plasma concentration of risdiplam metabolite (M1)Time frame: Week 21
- Part 1 - Cmax of risdiplamTime frame: Week 21
- Part 1 - AUC of risdiplamTime frame: Week 21
- Part 1 - Ctrough of risdiplamTime frame: Week 21
- Part 1 - Incidence of anti-drug antibodies (ADAs)Time frame: Through Week 96
- Part 1 - Change from baseline in serum concentration of total myostatinTime frame: Through Week 85
- Part 1 - Change from baseline in serum concentration of free latent myostatinTime frame: Through Week 85
- Part 1 - Change from baseline in serum concentration of mature myostatinTime frame: Through Week 85
- Part 1 - Percent change from baseline in the contractile area of skeletal muscle in the dominant thigh muscles as assessed by magnetic resonance imaging (MRI) in participants aged at least 5 yearsTime frame: Week 24 of combination treatment
- Part 1 - Percent change from baseline in the contractile area of skeletal muscle in the dominant calf muscles as assessed by MRI in participants aged at least 5 yearsTime frame: Week 24 of combination treatment
- Part 2 - Change from baseline in Revised Hammersmith Scale (RHS) total scoreTime frame: Week 72 of combination treatment (study Week 80)
Locations
29 sites in 12 countries. Site status is shown where the registry gives one.
Boston Childrens Hospital
Boston, Massachusetts
Columbia University Medical Center
New York, New York
Sydney Children's Hospital
Randwick, New South Wales, Australia
UZ Gent
Ghent, Belgium
Chr de La Citadelle
Liège, Belgium
British Columbia Children's Hospital
Vancouver, British Columbia, Canada
The Hospital for Sick Children
Toronto, Ontario, Canada
McGill University Health Centre - Glen Site
Montreal, Quebec, Canada
Clinical Hospital Centre Zagreb
Zagreb, Croatia
Policlinico Agostino Gemelli
Rome, Lazio, Italy
Fondazione IRCCS Istituto Neurologico ?Carlo Besta?
Milan, Lombardy, Italy
Asst Grande Ospedale Metropolitano Niguarda
Milan, Lombardy, Italy
Ospedali Riuniti Torrette di Ancona
Ancona, The Marches, Italy
Kobe University Hospital
Hyōgo, Japan
Kagoshima University Hospital
Kagoshima, Japan
National Center for Global Health and Medicine
Shinjuku-ku, Japan
Universitair Medisch Centrum Utrecht
Utrecht, Netherlands
Instytut Centrum Zdrowia Matki Polki
?ód?, Poland
Uniwersyteckie Centrum Kliniczne
Gda?sk, Poland
Uniwersytecki Szpital Kliniczny w Poznaniu
Późna, Poland
Klinika Neurologii I Wydzialu Lekarskiego WUM w Warszawie
Warsaw, Poland
Instytut Pomnik Centrum Zdrowia Dziecka
Warsaw, Poland
CHULC, E.P.E. - Hospital Dona Estefania
Lisbon, Portugal
Hospital de Santa Maria
Lisbon, Portugal
Hospital Universitario La Paz
Madrid, Spain
Hospital Universitario la Fe
Valencia, Spain
Hospital Sant Joan De Deu
Esplugues de Llobregas, Barcelona, Spain
Birmingham Heartlands Hospital
Birmingham, United Kingdom
John Radcliffe Hospital
Oxford, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.